$SXTC.US Su Xuantang, one of the few traditional Chinese medicine concept stocks listed on the Nasdaq. Domestic slice/processing factories are operating normally, but the U.S.-listed entity is in a difficult situation.
In FY2026, revenue was $1.138 million, down 34.6% year over year. Net loss was $6.205 million. Operating cash flow continued to be negative. In early 2026, it executed a 1-for-150 reverse stock split. In July, it completed a $9.0 million financing with warrants. It survives mainly through financing, and there are no signs of a fundamental turnaround.
Trading is thin, and the share price is driven largely by positioning of shares. Having factory operations does not necessarily mean the stock is safe—it is a typical “shell-maintenance/keep-the-listing” speculation target.
For information sharing only and does not constitute investment advice
In FY2026, revenue was $1.138 million, down 34.6% year over year. Net loss was $6.205 million. Operating cash flow continued to be negative. In early 2026, it executed a 1-for-150 reverse stock split. In July, it completed a $9.0 million financing with warrants. It survives mainly through financing, and there are no signs of a fundamental turnaround.
Trading is thin, and the share price is driven largely by positioning of shares. Having factory operations does not necessarily mean the stock is safe—it is a typical “shell-maintenance/keep-the-listing” speculation target.
For information sharing only and does not constitute investment advice